Cite
MLA Citation
David Schaer et al.. “Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition.” Journal for immunotherapy of cancer, vol. 3, no. 2, 2015, pp. 1–2. http://access.bl.uk/ark:/81055/vdc_100080441580.0x0003ab